Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) was upgraded by Cantor Fitzgerald from an “underweight” rating to a “neutral” rating in a research report issued on Wednesday, Marketbeat Ratings reports. The brokerage presently has a $69.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 11.96% from the company’s previous close.

The analysts wrote, “Emerging Safety Risks, but PBC Remains Intact. This morning, Intercept reported results demonstrating 3Q17 revenue growth to $36.8 million (excl. $4.1 million one-time increase in deferred revenue) from $31 million in 2Q17. While the FDA warning letter at the end of the quarter potentially shifts the risk-benefit profile of Ocaliva, an analysis of drug scripts provided by Intercept indicates that the sharp drop in scripts around the time of the news has since abated. Net ex-U.S 3Q17 sales increased to $4.7 million from $2.5 million in 2Q17 during the quarter, largely contributed from Germany and France. No formal guidance for the full-year was given, but management noted that they expect sequential quarterly growth for the balance of 2017. While we do not see a negative impact to our long-run commercialization in PBC, we believe the safety events reaffirm the uncertainty for Ocaliva’s use in NASH (where dosing is higher).””

ICPT has been the subject of a number of other research reports. Royal Bank Of Canada started coverage on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $244.00 target price for the company. Laidlaw cut their target price on shares of Intercept Pharmaceuticals from $118.00 to $90.00 and set a “hold” rating for the company in a research report on Friday, September 22nd. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Wedbush reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. Finally, Wells Fargo & Company reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $153.76.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. During the same quarter in the prior year, the firm earned ($3.59) EPS. The company’s revenue was up 697.9% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Upgraded at Cantor Fitzgerald” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/01/intercept-pharmaceuticals-inc-icpt-upgraded-at-cantor-fitzgerald.html.

In related news, CEO Mark Pruzanski sold 1,532 shares of Intercept Pharmaceuticals stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Lisa Bright sold 253 shares of Intercept Pharmaceuticals stock in a transaction on Friday, August 25th. The stock was sold at an average price of $111.31, for a total transaction of $28,161.43. Following the completion of the transaction, the insider now owns 23,324 shares in the company, valued at approximately $2,596,194.44. The disclosure for this sale can be found here. Insiders sold a total of 4,069 shares of company stock worth $325,974 in the last quarter. Insiders own 4.50% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. WFG Advisors LP grew its position in Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 125 shares during the last quarter. IFP Advisors Inc grew its position in Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 730 shares during the last quarter. Aperio Group LLC acquired a new stake in Intercept Pharmaceuticals in the 2nd quarter worth $212,000. SG Americas Securities LLC acquired a new stake in Intercept Pharmaceuticals in the 2nd quarter worth $235,000. Finally, QCM Cayman Ltd. acquired a new stake in Intercept Pharmaceuticals in the 2nd quarter worth $237,000. Hedge funds and other institutional investors own 82.81% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.